CEL-SCI Corp (CVM NYSE MKT) stock market data APIs
$3.8111
-0.78(-20.5%)
as of July 10, 2025
Try our APIs with
free plan!
CEL-SCI Corp Financial Data Overview
Price chart is built with
Anychart
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Prev. Close
3.8111
Open
3.0268
High
3.8462
Low
2.9058
52 wk Range
1.98-47.7
Market Cap
14 378 K
Shares Outstanding
5 135 K
Revenue
28 558
EPS
-2.3323
Beta
0.263
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CEL-SCI Corp data using free add-ons & libraries
Get CEL-SCI Corp Fundamental Data
CEL-SCI Corp Fundamental data includes:
- Net Revenue: 28 558
- EBITDA: -23 937 078
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CEL-SCI Corp News
New
CVM: Fiscal Year 2023 in Review
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2023 Update CEL-SCI Corporation (NYSE:CVM) reported fiscal year 2023 on December 22nd after filing its Form 10-K wi...
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
VIENNA, Va., December 22, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate...
CVM: NICE To Have Your Support
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Selected as Potential New Standard of Care CEL-SCI Corporation (NYSE:CVM) provided a pleasant surprise earlier this w...
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
VIENNA, Va., December 04, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multiki...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
